Heidelberg, Germany, May 20, 2021 -- Affimed N.V. (Nasdaq: AFMD), a 
clinical-stage immuno-oncology company committed to giving patients back 
their innate ability to fight cancer, announced today that its 2021 
Annual General Meeting of Shareholders (the "Annual Meeting") will be 
held on June 15, 2021 at 17:30 PM CET (11:30 AM EDT). Due to the 
continuing COVID-19 pandemic and out of concern for the health and 
safety of shareholders and other attendees, the Annual Meeting will be 
held virtually and can be followed by visiting 
https://www.globenewswire.com/Tracker?data=40CT10eRJID5CUy5eSFaJnZO_jxKtf3aDQVARoAdGwoi_W3NBWr5o-iF53NHpAVID-vFcAjOjg9HDqcU2la1FYq2rr8VaGwhZUA4gQqOg0SNSnfLfwvZyWKMhf_ZNOcVGL8O7KzVwrW49Z8lkhZg_AN5E9Jcrxfdvxor83-gMJI= 
www.virtualshareholdermeeting.com/AFMD2021, in accordance with the 
instructions provided in the notice of the meeting.  Shareholders will 
not be able to attend the Annual Meeting in person. 
 
   The notice and agenda of the Annual Meeting are available on Affimed's 
website at 
https://www.globenewswire.com/Tracker?data=M0BphNnwo7s2ZQhL08wD8nP53Q02vJrwcKEPq0vjHuETYKdAduD1w6Q1deecG7lQOX4i89mRz7QvcRE1NhwanEye2oz3QuNG9v86fgbLlyczl3OmHGzJE1XWmZgOZig0 
https://www.affimed.com/investors/ under "Annual Meeting", as well as 
the SEC's website at 
https://www.globenewswire.com/Tracker?data=40CT10eRJID5CUy5eSFaJiqRlfoeNBAd2-wg1Lb6e6sgtLmqHdQY7lMFLB2eaq6dyLbt_JsfAwiEQetYcEm8Dg== 
www.sec.gov. 
 
   About Affimed N.V. 
 
   Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company 
committed to giving patients back their innate ability to fight cancer 
by actualizing the untapped potential of the innate immune system. The 
company's proprietary ROCK(R) platform enables a tumor-targeted approach 
to recognize and kill a range of hematologic and solid tumors, enabling 
a broad pipeline of wholly-owned and partnered single agent and 
combination therapy programs. The ROCK platform predictably generates 
customized innate cell engager (ICE(R)) molecules, which use patients' 
immune cells to destroy tumor cells. This innovative approach enabled 
Affimed to become the first company with a clinical-stage ICE(R). 
Headquartered in Heidelberg, Germany, with offices in New York, New York, 
Affimed is led by an experienced team of biotechnology and 
pharmaceutical leaders united by a bold vision to stop cancer from ever 
derailing patients' lives. For more about the company's people, pipeline 
and partners, please visit: 
https://www.globenewswire.com/Tracker?data=40CT10eRJID5CUy5eSFaJgaSrhq6pCGvB67MYk9d5TY339id2FkoXLYq8Es03zQTKRAbC_0h654der4XY2Draw== 
www.affimed.com. 
 
 
 
   Investor Relations Contact 
 
   Alexander Fudukidis 
 
   Head of Investor Relations 
 
   https://www.globenewswire.com/Tracker?data=k2RS990yghIvBJNNL0sG2KfeGh3W6DimI7pwL3QhkqZf5uXpjxjVz-v1a5TFziMR_fM-x8UfTzg5jUU5yzbEK57CpiIQkQnonfvWSKUuytI= 
a.fudukidis@affimed.com 
 
   Tel.: +1 (917) 436-8102

(END) Dow Jones Newswires

May 20, 2021 16:30 ET (20:30 GMT)